Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Now that Project Data Sphere has established itself as a world-class data sharing platform, the group’s leadership is planning for its next phase of the struggle against cancer. Project Data Sphere's president Bill Louv talks to In Vivo about how the group has "raised the bar on what is possible to achieve in cancer research."
Latest From Innovation
ImmunoGen CEO: Solving Cancer’s Access Challenge With Data, Differentiation And A Big Dose of Bipartisanship
ImmunoGen CEO Mark Enyedy, a leading proponent of targeted ADC oncologics, explains to In Vivo how high risk – and dogged resilience – are central features of a challenging innovative landscape in cancer today. Despite some recent setbacks on the road to commercialization, science will continue to transform, bolstered by the industry's financial commitments; revolutionary new data sources, validated by patient-centered outcomes; and that persistent human intangible called hope.
GE Healthcare is using its artificial intelligence platform Edison to power a new generation of medical imaging apps and devices. At the annual European Congress of Radiology (ECR), In Vivo met with Mathias Goyen, GE Healthcare’s chief medical officer, Europe, to discuss the future of AI in radiology and how technology will transform practice.
Hip and knee replacement challenger firm Corin Group has a big ambition to revolutionize orthopedics with connected digital ecosystems and patient-specific concepts. That aim has come a step closer with its acquisition of robotic-assisted total knee replacement (TKR) company Omni Orthopaedics. Corin's Elvio Gramignano believes this approach will lead to real change in health care delivery.
David Lee, partner at Simon-Kucher & Partners, sits down for a fireside chat with serial entrepreneur Julia Hu to talk about virtual AI nurses and the future of chronic disease management. Hu founded Lark Health in 2011 with the goal of scaling personalized, digitally driven health care to anyone in the world.
Merck & Co.’s Keytruda is already elbowing its way into the top ten best-selling drugs. But it, and its expanding cohort of competitors, could be much bigger. Companies and investors are scrambling to identify the technology or technologies that can unlock checkpoint inhibitors’ potential in the 70% or more of tumors where they do not currently work. That activity is reflected across 2018’s licensing deals, M&A and financings.
No NASH treatments are on the market yet, but Phase III data readouts are emerging, mid-stage drugs are demonstrating their capabilities and combinations are in view.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.